Британский журнал исследований Открытый доступ

Абстрактный

The Difference between SGLT2 and DPP-4 Inhibitors on Glucose Fluctuation in Patients with Type 2 Diabetes

Hiroshi Nomoto and Hideaki Miyoshi

Various oral and parental hypoglycemic agents have been developed to achieve adequate glycemic control in patients with type 2 diabetes mellitus. Because of the relatively high prevalence of cardiovascular events in this patient population, it is also necessary to minimize glucose fluctuation to prevent atherosclerotic disease. Two different types of hypoglycemic agents, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter 2 inhibitors, appear to control glucose variability to a similar extent, but their efficacy might depend somewhat on the patient’s background. To clarify which type of drug is more appropriate for use in a given patient, further investigation is needed.